跳至主要内容
临床试验/NCT04343560
NCT04343560已完成不适用

Effects of Abnormal Steroid Metabolome on Bone Strength and Quality, Bone Density, Bone Remodeling, and Body Composition in Patients With MACS and Healthy Volunteers.

Mayo Clinic1 个研究点 分布在 1 个国家目标入组 380 人开始时间: 2019年2月21日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Mayo Clinic
入组人数
380
试验地点
1
主要终点
BV/TV ratio

研究概览

简要总结

Adrenal adenoma is detected in 5-7% of adults and demonstrates mild autonomous cortisol secretion (MACS, dexamethasone suppression test >1.8 mcg/dl) in 50% of individuals with adenoma. Published reports suggest a 48%-52% 2-year incidence of new vertebral fractures in patients with MACS without any significant changes in bone density measurements. A disproportionate decrease in bone quality versus density or other factors such as sarcopenia potentially contribute to development of new vertebral fractures. Determining which specific abnormalities in the steroid metabolome affect bone density, quality and strength as well as bone remodeling markers and body composition will potentially serve as a diagnostic biomarker of clinical significance.

详细描述

In this study, we will determine whether patients with MACS (versus healthy age and sex matched controls) demonstrate: 1) decreased bone strength and quality disproportionate to the decrease of bone density and 2) abnormalities in the steroid metabolome correlate with the degree of abnormalities in bone parameters. In a cross-sectional study of 75 patients with MACS and 75 age- and sex-matched healthy controls, we will determine the relationship of the steroid metabolome to measurements of bone density, quality and strength, bone turnover markers, as well as body composition. All patients will be interviewed in regards to their health, to include questions on bone health, frailty, cognition (NIH toolbox), and quality of life. We will measure 1) BMD (bone mineral density) at the lumbar spine, hip and radius and body composition using dual-energy X ray absorptiometry (DXA), 2) radial and tibial bone microstructure by high-resolution peripheral quantitative computed tomography (HR-pQCT), 4) bone turnover markers (osteocalcin, PINP, CTx, sclerostin). 5) Age reader measurement, 6) hand grip measurement, 7) 6 minute walk test. All patients will provide a 24 h urine for steroid metabolome analysis. For primary outcomes, we will determine if steroid metabolome profiling better predicts abnormal bone strength (as measured by trabecular bone volume/tissue volume [BV/TV] ratio).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with MACS
  • Age 18-no maximum
  • exogenous steroids therapy within the last 5 years ( for more than 3 months , prednisone equivalent >7.5 mg daily)
  • steroid hormone replacement therapy
  • any drug therapy affecting bone metabolism
  • recent fracture

排除标准

  • exogenous steroids therapy within the last 5 years ( for more than 3 months , prednisone equivalent >7.5 mg daily)
  • steroid hormone replacement therapy ( for adrenal insufficiency, hypogonadism, menopause)
  • therapy for osteoporosis
  • any drug therapy affecting bone metabolism
  • comorbidities affecting steroid metabolome or bone metabolism
  • recent fracture

结局指标

主要结局

BV/TV ratio

时间窗: 0-24 months

measured by computed tomography

steroid metabolome

时间窗: 0-24 months

24h urine steroid profiling

次要结局

未报告次要终点

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Irina Bancos

Principal Investigator

Mayo Clinic

研究点 (1)

Loading locations...

相似试验